login
  Password reminder
Vascular News
Contact the editor Visit Vascular News Twitter feed Visit Vascular News Facebook page
 

Pulsar Stent shows positive outcomes in 4EVER clinical study


Wednesday, 23 May 2012 12:34
Pulsar
Pulsar

The six-month results from the prospective, multicentre, single-arm 4EVER study (Trial investigating the safety of 4F endovascular treatment of infra-inguinal arterial stenotic disease) demonstrate efficacy and safety of the Pulsar Stent System (Biotronik) in 120 superficial femoral arterypatients.


Analysis of the 120 patients showed excellent device performance, very promising patency rates and convincing evidence of the benefits of lower limb intervention on a 4F platform. Although only the interim results were presented at the Leipzig Interventional Course (LINC 2012) in Leipzig, Germany, Biotronik announced that analysis of the full cohort has recently been made available.

The 4EVER study was initiated by Marc Bosiers, Dendermonde, Belgium, to investigate the efficacy of Pulsar stents and also the feasibility of treating patients with Biotronik’s 4F devices namely the Fortress 4F sheath, together with the Astron Pulsar and Pulsar-18 SE stents.

In total, 120 patients were recruited into the study. Six-month primary patency is documented as being as high as 90.0%. Average lesion length in the Pulsar-18 subgroup was 10.5cm. On the 4F intervention side, Bosiers presented a complication rate of only 3.3% and a mean manual compression time of around 8 minutes, halving the time experienced when using 6F.


Technical success of 100% clearly supports the possibility for minimally invasive peripheral intervention of the lower limb. When asked during the Biotronik symposium at LINC 2012 whether all patients can be treated with 4F, Koen Deloose, Dendermonde, Belgium, responded, “4F is sufficient for the majority of endovascular treatments.”

Pulsar-18 stents provide an innovative design of ultrathin nitinol struts coated with Probio, a silicone carbide layer that improves the stent’s haemocompatibility and biocompatibility, which is believed to contribute to its positive clinical results. Pulsar-18 is available in diameters of 4–7mm and 20–200mm lengths deliverable through a 4F sheath.


The primary endpoint data, primary patency at twelve months, is expected to be presented at CIRSE (Cardiovascular and Interventional Radiological Society of Europe) 15–19 September 2012 in Lisbon, Portugal.




Add New Comment

Related Items


Most popular


OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression
Wednesday, 18 Jun 2014
An analysis of the OVER trial presented at the Society for Vascular Surgery Vascular Annual Meeting (SVS, 5–7 June, Boston, USA) shows that the development of endoleaks were common in patients ... OVER analysis: Endoleak does not predict reduced long-term survival but negatively impacts sac regression

Medtronic to acquire Covidien for US$42.9 billion in cash and stock
Monday, 16 Jun 2014
The acquistion creates a medical technology and services company with a comprehensive product portfolio and broad global reach. Medtronic to acquire Covidien for US$42.9 billion in cash and stock

FDA advisory panel unanimously recommends approval for Lutonix DCB
Friday, 13 Jun 2014
Lutonix DCB is one step closer to becoming the first US FDA-approved drug-coated balloon for the treatment of patients with femoropopliteal occlusive disease. FDA advisory panel unanimously recommends approval for Lutonix DCB

Features


SPECT can predict cardiovascular mortality in elective aneurysm repair patients
Wednesday, 12 Mar 2014
Kimihiro Komori and Yosuke Inoue analyse the results of a study that concluded that preoperative pharmacologic stress myocardial perfusion SPECT is not only safe, but is also a useful method to ... SPECT can predict cardiovascular mortality in elective aneurysm repair patients

Hybrid techniques for the arch: are they effective and durable?
Monday, 17 Feb 2014
Piergiorgio Cao writes that despite the perioperative mortality risk, the late outcome of endovascular arch repair presents a low rate of aorta-related deaths and reinterventions and acceptable mid-... Hybrid techniques for the arch: are they effective and durable?

Profiles


Cliff Shearman
Thursday, 03 Jul 2014
A former president of the Vascular Society of Great Britain and Ireland, Cliff Shearman was ... Cliff Shearman

Andrew Holden
Tuesday, 11 Feb 2014
Andrew Holden has been involved in the investigation of several endovascular devices for the ... Andrew Holden

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions